By Fineline Cube 
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received approval from the US Food and Drug Administration (FDA) to initiate a Phase I clinical study for its HDM1010 drug in type 2 diabetes (T2D).
HDM1010 Profile
HDM1010 is a fixed-dose combination (FDC) drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd., a wholly owned subsidiary of Huadong Medicine. The drug combines HDM1002, an in-house developed oral GLP-1 receptor agonist, with an SGLT2 inhibitor.
Mechanism and Benefits
HDM1002 activates the GLP-1 receptor, inducing the production of cyclic adenosine monophosphate (cAMP). This mechanism delivers potent effects in improving glucose tolerance, lowering blood sugar, and promoting weight loss. HDM1010 has demonstrated a favorable safety profile in preclinical studies.-Fineline Info & Tech